Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 7, 2006; 12(1): 157-158
Published online Jan 7, 2006. doi: 10.3748/wjg.v12.i1.157
Published online Jan 7, 2006. doi: 10.3748/wjg.v12.i1.157
Table 1 Comparisons between before and after therapy (mean±SE)
| Before | After | |
| Bradygastria (%) | 54.0 ± 7.4 | 77.4 ± 5.6a |
| Normogastria (%) | 42.4 ± 7.5 | 18.6 ± 5.2a |
| Tachygastria (%) | 3.2 ± 1.8 | 4.0 ± 4.0 |
| PR of badygastria (%) | 1.3 ± 0.1 | 0.8 ± 0.1a |
| PR of normogastria (%) | 2.5 ± 0.5 | 1.8 ± 0.5a |
| PR of tachygastria (%) | 2.1 ± 0.5 | 1.7 ± 0.5 |
| DF (c/min) | 2.3 ± 0.1 | 1.9 ± 0.1 |
| Gastrointestinal symptoms | 1.8 ± 0.2 | 2.2 ± 0.5 |
| Total score |
- Citation: Kinekawa F, Matsuda K, Masaki T, Kurokohchi K, Yoneyama H, Inoue H, Kurata H, Uchida Y, Watanabe S, Kuriyama S. Percutaneous local therapies for hepatocellular carcinoma impair gastric function. World J Gastroenterol 2006; 12(1): 157-158
- URL: https://www.wjgnet.com/1007-9327/full/v12/i1/157.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i1.157